Erratum: Tolvaptan for heart failure patients with volume overload (Cardiovascular Drugs and Therapy DOI: 10.1007/s10557-011-6298-4);Tolvaptan for heart failure patients with volume overload

Cardiovascular Drugs and Therapy

Volumn 25, Issue SUPPL. 1, 2011, Pages 1-4

  Hori, Masatsugu ^a  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN I; ANGIOTENSIN II; DIURETIC AGENT; EPLERENONE; FUROSEMIDE; LOOP DIURETIC AGENT; PLACEBO; RENIN; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN;

ARTICLE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DIURETIC THERAPY; DIZZINESS; DOSE RESPONSE; DRUG DETERMINATION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MECHANISM; EDEMA; ELECTROLYTE DISTURBANCE; FLUID RETENTION; HEART VENTRICLE OVERLOAD; HORMONE ACTION; HUMAN; HYPONATREMIA; HYPOPROTEINEMIA; HYPOTENSION; LOW DRUG DOSE; NATRIURESIS; OSMOTIC PRESSURE; OUTCOME ASSESSMENT; PATHOGENESIS; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM RESTRICTION; VASOPRESSIN RELEASE; WATER DEPRIVATION;

EID: 79955451582     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-011-6360-2     Document Type: Erratum

References (22)

1. Japanese Circulation Society. Guidelines for the diagnosis and treatment of cardiovascular disease (Joint Study Gr oup Report 2004): guidelines for the diagnosis and treatment of chronic heart failure (revised 2005). http://www.j-circ.or.jp/guideline/pdf/JCS2005-matsuzaki-h.pdf. Accessed 27 Oct 2010.
2. RW Schrier WT Abraham 1999 Hormones and hemodynamics in heart failure N Engl J Med 341 577 585 10451464 10.1056/NEJM199908193410806 1:CAS:528: DyaK1MXlvVOnsbY%3D (Pubitemid 29384167)
3. SR Goldsmith M Gheorghiade 2005 Vasopressin antagonism in heart failure J Am Coll Cardiol 46 1785 1791 16286160 10.1016/j.jacc.2005.02.095 1:CAS:528:DC%2BD2MXht1SrtbzO (Pubitemid 41579797)
4. Rivera-Santos A, Star R. Sodium: volume depletion and hyponatremia. In: Seldin D, Giebisch G, editors. Diuretic agents-clinical physiology and pharmacology. San Diego: Academic; 1997. p. 559-69.
5. Palmer BF. Potassium disturbances associated with the use of diuretics. In: Seldin D, Giebisch G, editors. Diuretic agents-clinical physiology and pharmacology. San Diego: Academic; 1997. p. 571-83.
6. B Pitt F Zannad WJ Remme, et al. 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure N Engl J Med 341 709 717 10471456 10.1056/NEJM199909023411001 1:CAS:528:DyaK1MXmtVyrurk%3D (Pubitemid 29407370)
7. F Zannad JJ McMurray H Krum, et al. 2011 Eplerenone in patients with systolic heart failure and mild symptoms N Engl J Med 364 11 21 21073363 10.1056/NEJMoa1009492 1:CAS:528:DC%2BC3MXisValuw%3D%3D
8. HJ Adrogué NE Madias 2000 Hyponatremia N Engl J Med 342 1581 1589 10824078 10.1056/NEJM200005253422107 (Pubitemid 30340505)
9. MS Cuffe RM Califf KF Adams, et al. 2002 Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial JAMA 287 1541 1547 11911756 10.1001/jama.287.12.1541 1:CAS:528: DC%2BD38XisVegt78%3D (Pubitemid 34269999)
10. 2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. Cardiovasc Drugs Ther. 2011; submitted.
11. Matsuzaki M, Hori M, Izumi T, et al. Effects of tolvaptan on volume overload in Japanese patients with heart failure: Results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Cardiovasc Drugs Ther. 2011; submitted.
12. Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST Study). Cardiovasc Drugs Ther. 2011; submitted.
13. Fukunami M, Matsuzaki M, Hori M, et al. Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study. Cardiovasc Drugs Ther. 2011; submitted.
14. Inomata T, Izumi T, Matsuzaki M, et al. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther. 2011; submitted.
15. Onogawa T, Sakamoto Y, Nakamura S, et al. Effects of tolvaptan on systemic and renal hemodynamic function in dogs with congestive heart failure. Cardiovasc Drugs Ther. 2011; submitted.
16. Miyazaki T, Sakamoto Y, Yamashita T, et al. Anti-edematous effects of tolvaptan in experimental rodent models. Cardiovasc Drugs Ther. 2011; submitted.
17. Furukawa M, Hirota M, Okumura H, et al. Nonclinical pharmacokinetics of tolvaptan. Cardiovasc Drugs Ther. 2011; submitted.
18. Oi A, Ito N, Morishita K, et al. Nonclinical safety profile of tolvaptan. Cardiovasc Drugs Ther. 2011; submitted.
19. Y Yamamura S Nakamura S Itoh, et al. 1998 OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats J Pharmacol Exp Ther 287 860 867 9864265 1:CAS:528:DyaK1MXjvVShsw%3D%3D (Pubitemid 29131593)
20. T Miyazaki H Fujiki Y Yamamura S Nakamura T Mori 2007 Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials Cardiovasc Drug Rev 25 1 13 17445084 10.1111/j.1527-3466.2007.00001.x 1:CAS:528:DC%2BD2sXht12kurrJ (Pubitemid 46625287)
21. T Hirano Y Yamamura S Nakamura T Onogawa T Mori 2000 Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats J Pharmacol Exp Ther 292 288 294 10604960 1:CAS:528:DC%2BD3cXhslGktg%3D%3D (Pubitemid 30026383)
22. LC Costello-Boerrigter WB Smith G Boerrigter, et al. 2006 Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure Am J Physiol Ren Physiol 290 F273 F278 10.1152/ajprenal.00195.2005 1:CAS:528:DC%2BD28XhsFKit7Y%3D (Pubitemid 43724981)